Discover our pathA clear Vision of the Market
Cancer Diagnostics is a highly fragmented, technology-driven market.
Those who succeed in integrating companies by combining markets and technologies will achieve economies of scale
both at the corporate and product level,
gaining a significant and sustainable competitive advantage in the long term.
This is highly valued by the market and rewarded with a significant premium.
Those who succeed in integrating companies by combining markets and technologies will achieve economies of scale
both at the corporate and product level,
gaining a significant and sustainable competitive advantage in the long term.
This is highly valued by the market and rewarded with a significant premium.
ALIKO SCIENTIFICVision
& Mission
Our vision is the integration of innovative tehcnologies at the forefront of Cancer Diagnostics.
By combining these technologies, we create cost effective synergies in prediction, early detection, and precise typing of cancers for different organs.
We wanto to do so by expanding the proprietary range of oncology diagnostics products both with internal R&D and M&A.
By combining these technologies, we create cost effective synergies in prediction, early detection, and precise typing of cancers for different organs.
We wanto to do so by expanding the proprietary range of oncology diagnostics products both with internal R&D and M&A.
Join our Mission
ALIKO SCIENTIFIC is open to both corporate and commercial partnerships.
Feel free to contact us for potential collaborations.
Feel free to contact us for potential collaborations.
We address a Growing ConcernThe Shortage of Pathologists
The shortage of pathologists is a growing issue globally.
In the United States, the number of pathologists decreased by 17.53% over a decade, with only 3.94 pathologists per 100,000 people in 2017.
This shortage is especially concerning given the increased number of cancer cases requiring diagnosis. While some advancements in technology and workflow efficiencies have allowed pathologists to handle more cases, there is still a risk of overwork and burnout, which can affect diagnostic accuracy and patient care.
The anticipated retirements and the aging population further predict a deficit of around 5,000 full-time equivalent pathologists by 2030 (JAMA Network).
Here are the solutions we are working on:
In the United States, the number of pathologists decreased by 17.53% over a decade, with only 3.94 pathologists per 100,000 people in 2017.
This shortage is especially concerning given the increased number of cancer cases requiring diagnosis. While some advancements in technology and workflow efficiencies have allowed pathologists to handle more cases, there is still a risk of overwork and burnout, which can affect diagnostic accuracy and patient care.
The anticipated retirements and the aging population further predict a deficit of around 5,000 full-time equivalent pathologists by 2030 (JAMA Network).
Here are the solutions we are working on:
AI and Digital Pathology
The industry can develop AI-powered diagnostic tools that assist pathologists in identifying cancerous cells more quickly and accurately. Digital pathology platforms can automate routine tasks, such as tissue analysis and pattern recognition, reducing the time required for manual review.
Automated Diagnostic Platforms
Creating automated diagnostic systems that integrate with laboratory workflows can streamline the processing of biopsy samples, making the diagnostic process faster and more reliable. These platforms can handle high volumes of tests with minimal human intervention, alleviating some of the pressures on pathologists.
Integrated Diagnostic Solutions
The industry can create integrated diagnostic platforms that combine molecular, genetic, and imaging data to provide a comprehensive view of a patient’s condition. This holistic approach can lead to quicker, more precise diagnoses, reducing the reliance on traditional pathology alone.
Remote Diagnostic Services
The industry can offer telepathology services, enabling remote access to pathology expertise. This allows smaller healthcare facilities or those in underserved areas to send digital images to specialized pathologists for diagnosis, improving access to quality care.
Every Organ has specific Diagnostic paths. Here relies the efficiency research.Organ Based Cancer Diagnostic
AI, Automation, Integration, Remote Diagnostics. It works only if is verticalized on Organs.
Organ Based Diagnostics an VerticalizationOUR INDUSTRIAL STRATEGY
START FROM DATA
We are building integrate solutions, on the most common cancer
Lung Cancer
12.3% of total cases. This is the leading cause of cancer deaths worldwide, often linked to smoking and environmental factors.
Breast Cancer
11.7% of total cases. It is the most common cancer among women globally.
Colorectal Cancer
10.0% of total cases. This includes cancers of the colon and rectum, influenced by diet, lifestyle, and genetic factors.
Prostate Cancer
7.3% of total cases. It is the second most common cancer among men.
Stomach (Gastric) Cancer
5.6% of total cases. Incidence rates are higher in East Asia, particularly Japan and Korea.
Liver Cancer
4.7% of total cases. Risk factors include hepatitis infection and heavy alcohol consumption.
Cervical Cancer
3.1% of total cases. It remains a significant cause of cancer mortality particularly in low- and middle-income countries.
Bladder & Kidney Cancer
2.6% of total cases. Risk factors include smoking and exposure to industrial chemicals.
ORGAN ORIENTED R&D
Enhanced diagnostic efficacy directly translates into increased revenue generation for our client laboratories and healthcare facilities, as they are able to offer more accurate, timely, and high-value diagnostic services.
Organ-Specific Diagnostics
Each organ in the body has unique characteristics and cellular structures, which means that cancer manifests differently in each one.
As a result, cancer diagnostics must be tailored to the specific traits of each organ to achieve accurate detection and diagnosis.
This organ-specific approach is necessary because cancers can vary widely in their behavior, molecular markers, and how they respond to treatments.
Advanced diagnostics, such as molecular testing, immunohistochemistry, and genetic profiling, are often used to identify specific markers and mutations unique to cancers in different organs.
These diagnostics not only enable early detection but also guide personalized treatment plans, leading to better patient outcomes.
This is our Mission
As a result, cancer diagnostics must be tailored to the specific traits of each organ to achieve accurate detection and diagnosis.
This organ-specific approach is necessary because cancers can vary widely in their behavior, molecular markers, and how they respond to treatments.
Advanced diagnostics, such as molecular testing, immunohistochemistry, and genetic profiling, are often used to identify specific markers and mutations unique to cancers in different organs.
These diagnostics not only enable early detection but also guide personalized treatment plans, leading to better patient outcomes.
This is our Mission
Looking for Growth, we are seeking for oppotunities.OUR GROWTH ROADMAP
The 3 pillars of our growth
Regional DistributorsAgreements or M&A
for market development
We are seeking distributors in the EU, USA, LATAM, and the Middle East who are already active in the field of anatomical pathology and are interested in integrating with our group.
Together, we aim to expand our reach and enhance our impact in cancer diagnostics.
Together, we aim to expand our reach and enhance our impact in cancer diagnostics.
Vertical integrationM&A on Cancer Diagnostics SME
IWe are committed to vertical integration with other SMEs, combining our strengths to create a more comprehensive and efficient approach to cancer diagnostics, driving innovation and expanding our capabilities in the anatomical pathology field.
Scientific community engagement and New Products Development
We actively engage in new product development and collaborate with the scientific community to ensure our solutions remain at the forefront of cancer diagnostics, meeting the evolving needs of patients and healthcare professionals.
Join our Mission
ALIKO SCIENTIFIC is open to both corporate and commercial partnerships.
Feel free to contact us for potential collaborations.
Feel free to contact us for potential collaborations.
Which Companies are we looking for? M&A Strategy
ALIKO SCIENTIFIC is actively seeking to acquire innovative, high-potential companies in regions of the world not currently covered by its operations, as part of its strategy to expand and integrate advanced diagnostic technologies globally.
Dark Room Pictures from IKONISYS world
Get in touch
Come and visit our quarters or simply send us an email anytime you want. We are open to all requests.
Address
5 Science Park, New Haven, Connecticut
06511 - USA
06511 - USA
Call us
+1.203.776.0791
corporate@ikonisys.com
Are you a small medium sized company in this fields?Merger & Acquisition Targets
ALIKO SCIENTIFIC also welcomes opportunities to acquire also university spin-offs and R&D centers, further supporting its goal of expanding and integrating advanced diagnostic technologies worldwide.
LIQUID BIOPSY AND CTC
The automated screening of biological tissue for gene abnormalities using an automated fluorescence microscope to analyze fluorescence in situ hybridized (FISH) samples is provided.
MOLECULAR BIOLOGY
An automated, highly sensitive, specific and potentially quantitative detection method using an automated microscope for identifying and enumerating rare cancer cells in blood and other fluids.
NGS AND GENOMICS
A computer controlled method for detecting and diagnosing a rare cell type in a tissue sample, predictive ereditary tumors.
IMMUNO
An automated method for monitoring the efficacy over time of therapy of a cancer or hyperplasia in a patient. Provides an approach for treatment monitoring, determining response to therapy.
DEVICE AND REAGENTS
An approach to perform various image processing functions which may be employed to implement the automated fluorescence in situ hybridization method.
FISH PROBES
A method that combines immunohistochemistry and fluorescence in situ hybridization techniques, for detecting and quantitating multiple and unique fluorescent signals from a cell sample.
ELISA
An imaging system comprising an image intensifier and a CMOS image sensor, that provides fast capture speed and high sensitivity. Enables both the capture speed and sensitivity requirements for automated microscopy designed to detect signals in a biological sample.
AI AND IMAGING
Automated microscopic analysis of a plurality of data-encoded microscope slides. The data written to or read from the slides may comprise images, analysis protocols, analytic results and other clinically relevant data.